Interactions with cells is our passion!

Learn how IgG 3-43 blocks tumor cell growth both in vivo and in vitro.

We offer cutting edge technology that provides our customers an advantage when developing new pharmaceuticals.

Our third generation biosensors’ technology is unique and patented.

It reduces animal testing and makes the drug development process more efficient and cost effective.


Swedish press releases including regulatory releases are available in our Swedish news room. The English newsroom can be found here.



May 7 - Annual General Meeting

Attana are inviting shareholder for an AGM. Follow this link for information about the daily schedule, only in Swedish.

May 16 & 17 - GDDIF

Attana are presenting and exhibiting at the Global Discovery to Development Innovation in Amsterdam. Welcome to join us and contact us for more information.

June 11 - SME-day

Attana will be attending Småbolagsdagen (SME-day) at Sheraton Hotel Stockholm hosted by Aktiespararna where Teodor Aastrup, CEO & Founder of Attana, will present the company and respond to questions.

June 18 to 20 -  Advances in the Applications of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells

Attana to present scientific results at a conference for antibodies in clinical oncology on Cyprus. Welcome to listen or contact us for more information.

September 2 to 5 - CLINAM Summit

Attana are presenting recent discoveries of nanoparticles for therapeutic applications at the 11th European and Global Summit for Clinical Nanomedicine, Targeted Delivery and Precision Medicine in Basel. Welcome to listen or contact us for more information.


Greta Arwidssons v. 21, 114 19 Stockholm, Sweden.

Subscribe for information



© Attana 2018 | Attana AB